RxSight, Inc. to Report Second Quarter 2022 Financial Results on August 8, 2022
RxSight, Inc. (NASDAQ: RXST) will report its Q2 2022 financial results on August 8, 2022, after market close. A conference call is scheduled for 1:30 PM PT / 4:30 PM ET to discuss these results. Interested parties can access a live and archived webcast via the Investors page on RxSight's website. The company is focused on improving post-cataract surgery vision with its unique RxSight Light Adjustable Lens system, which includes advanced ActivShield technology. More details are available on their website.
- RxSight's Light Adjustable Lens system is the first commercially available IOL technology that allows customization of visual acuity post-surgery.
- The inclusion of ActivShield technology offers enhanced UV protection for patients.
- None.
ALISO VIEJO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it will report financial results for the second quarter 2022 after the market close on Monday, August 8, 2022. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.rxsight.com, on the Investors page in the News and Events section. Participants may register for the call here. While not required, it is recommended participants join 10 minutes prior to the event start. Instructions are provided (including a dial-in option) to ensure the necessary audio applications are downloaded and installed.
About RxSight, Inc.
RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The LAL now features ActivShield™ technology, a revolutionary UV protection layer built into the lens. Additional information about RxSight can be found at www.rxsight.com.
Company Contact:
Shelley Thunen
Chief Financial Officer
IR@rxsight.com
FAQ
When will RxSight report its Q2 2022 financial results?
What time is the conference call for RxSight's financial results?
How can I access the RxSight financial results conference call?
What is ActivShield technology in RxSight's products?
